Oncology continues to be a hotbed of innovation, with over 100 new cancer treatments expected to launch in the next five years alone. This frantic activity makes oncology one of the key growth engines of the biopharmaceutical industry and underpins its status as the dominant therapy area, generating $223 billion of global sales in 2023, at ex-manufacturer prices.

However, achieving commercial success in oncology is becoming increasingly difficult. Innovators face overwhelming complexity, opportunity fragmentation and a widening ‘innovation readiness’ gap, as healthcare systems cannot keep up with the pace of oncology innovation to effectively adopt new therapies.

A panel of EMEA strategy consulting experts will discuss case study examples of how successful oncology launches have mastered three strategic pillars—healthcare system readiness, value and evidence, and stakeholder engagement.

Join us to explore the evolving oncology innovation landscape, learn how to navigate a challenging environment, and master launch excellence to fulfil the promise of ground-breaking transformational therapies.

3 key takeaways:

• There is an overwhelming pace of scientific advances in oncology with novel modalities like ADCs, bispecific antibodies and radiopharmaceuticals offering transformative potential for cancer care
• Oncology innovators face a highly complex and competitive environment, marked by rapid innovation, fragmented patient populations, and healthcare systems that are operationally and financially unprepared to adopt new products effectively
• Excellent oncology launches must master the three strategic pillars—healthcare system readiness, value and evidence, and stakeholder engagement

Speakers:

Dr. Stefan Lutzmayer
Senior Consultant, EMEA Thought Leadership, IQVIA

Kirstie Scott
Senior Consultant, EMEA Thought Leadership, IQVIA

Cristina Alzaga-Chaudhry
EMEA LEAD, Commercial Strategy & Transformation Commercial Services, IQVIA

Parmender Dahiya
Associate Principal, Strategy Consulting EMEA, IQVIA